ClinicalTrials.gg
CompletedNCT04030143Updated Nov 18, 2023Results posted

A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder

A Phase 1/2 interventional study of Aripiprazole and Aripiprazole in Schizophrenia and Bipolar I Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 19 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
266
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
39th of 125
266 · median 130
Started
2019
with 5 others
Phase 1/2
2 of 126
none open now
Registered
118th of 126
by date
Lead sponsor
44 of 126
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 39th largest by enrollment of the 125 interventional ones that give a count, is one of 6 that started in 2019, is one of 2 in phase 1/2, and was the 118th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this trial is to determine the safety and tolerability of multiple-dose administrations of aripiprazole, to establish the similarity of aripiprazole concentrations on the last day of the dosing interval following the final administration of aripiprazole into the gluteal muscle site, and to establish the similarity of aripiprazole exposure over the dosing interval following the administration of aripiprazole into the gluteal muscle site in adult participants with schizophrenia or bipolar I disorder.

03

Conditions studied

  • Schizophrenia
  • Bipolar I Disorder

Browse trials for

Keywords

  • Aripiprazole
  • Aripiprazole Intramuscular Depot
  • Gluteal Muscle
  • Long Acting Injection
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A current diagnosis of schizophrenia or bipolar I disorder, as defined by , Fifth Edition (DSM-5) criteria.
  • of 18 to 35 kilograms per meter square (kg/m\^2).
  • On a stable dose of an atypical oral antipsychotic medication for at least 2 months prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Participants who have:

    • Met criteria for substance use disorder within the past 180 days.
    • A positive drug screen for drugs of abuse
  • Use of any psychotropic medications other than their current non-aripiprazole antipsychotic or mood stabilizer(s) medication; or participants who use more than one antipsychotic or mood stabilizer(s) medication at screening.
  • Females who are pregnant, breast-feeding, lactating, and/or have a positive pregnancy test result prior to receiving medicinal product (IMP). A negative serum pregnancy test must be confirmed prior to the first dose of IMP for all female participants.
  • Any major surgery within 30 days prior to enrollment or scheduled/elective surgery during the trial.
  • Evidence of organ dysfunction or any deviation from normal in the physical, electrocardiographic, or clinical laboratory examinations.
  • Participants currently in an acute relapse of schizophrenia.
  • Participants with a current DSM-5 diagnosis other than schizophrenia or bipolar I disorder, including schizoaffective disorder, major depressive disorder, delirium, dementia, amnestic, or other cognitive disorders. Also, participants with borderline, paranoid, histrionic, or antisocial personality disorder.
  • Participants with a history of neuroleptic malignant syndrome or clinically significant tardive dyskinesia.
  • History of any significant drug allergy or known or suspected , in particular to aripiprazole or other quinolinones.
  • History of or current hepatitis or acquired immunodeficiency syndrome or carriers of surface antigen (HBsAg) or antibodies (anti-HCV), and/or (HIV) antibodies.
  • Participants deemed intolerant of receiving injections.
  • Participants who have had electroconvulsive therapy within 2 months of administration of IMP.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
266 participants (actual)

Study arms

  • Experimental
    Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder

    Participants with schizophrenia or bipolar I disorder received aripiprazole 2 month (2M) long-acting injection (LAI) 960 milligrams (mg) for a total of 4 injections administered every 56 days (± 2 days) over the course of 32 weeks.

    Drug: Aripiprazole

  • Experimental
    Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder

    Participants with schizophrenia or bipolar I disorder received aripiprazole IM 400 mg, for a total of 8 injections administered every 28 days (± 2 days) over the course of 32 weeks.

    Drug: Aripiprazole

Interventions

  • Administered as an intramuscular (IM) depot injection.

    Also known as: OPC-14597, Lu AF41155

  • Administered as an IM depot injection.

    Also known as: OPC-14597, Lu AF41155

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Treatment-Emergent Adverse Events (TEAEs)

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. A TEAE is defined as an AE that started after investigational medicinal product (IMP) treatment; or if the event was continuous from baseline and was serious, IMP-related, or resulted in death, discontinuation, interruption, or reduction of the IMP.

    Time frame: From first dose of study drug up to 56 days (2M LAI 960 mg) or 28 days (IM depot 400 mg) post last dose of study drug (up to approximately 11 months)

  2. Number of Participants With Potentially Clinically Relevant Vital Signs Abnormalities

    Potentially clinically significant vital sign abnormalities included: heart rate supine (high: \>120 beats per minute \[BPM\] and increase \>=15 BPM; low: \<50 BPM and decrease \>=15 BPM), systolic blood pressure supine (high \>180 (millimetres of mercury \[mmHg\] and increase \>=20 mmHg); low: \<90 mmHg and decrease \>=20 mmHg), diastolic blood pressure supine (high: \>105 mmHg and increase \>=15 mmHg; low: \<50 mmHg and decrease \>=15 mmHg), heart rate standing (high: \>120 BPM and increase \>=15 BPM), systolic blood pressure standing (high: \>180 mmHg and increase \>= 20 mmHg; low: \<90 mmHg and decrease \>=20 mmHg), diastolic blood pressure standing (high: \>105 mmHg and increase \>=15 mmHg), weight in kilograms (kg) (high: increase \>=7%; low: decrease \>=7%), temperature (high: \>=37.8 degree celsius \[°C\] and increase \>=1.1°C), orthostatic hypotension (low: \>=20 mmHg decrease in systolic blood pressure and \>=25 BPM increase in heart rate from supine to standing.

    Time frame: From first dose of study drug up to Day 225

  3. Number of Participants With Potentially Clinically Relevant Electrocardiogram (ECG) Abnormalities

    Potentially clinically significant ECG abnormalities included rate: bradycardia (vent \<=50 BPM\] and decrease \>=15 BPM); rhythm: sinus bradycardia (\<= 50 BPM and decrease \>= 15 BPM and no current diagnosis of atrial fibrillation, atrial flutter, or other rhythm abnormality); supraventricular premature beat (not present at baseline and present post baseline); ventricular premature beat (not present at baseline and present post baseline); conduction: right bundle branch block (not present at baseline and present post baseline); ST/T morphology: myocardial ischemia and symmetrical T-wave inversion (not present at baseline and present post baseline), QTcB, QTcF, and QTcN (\>=450 milliseconds \[msec\] and \>= 10% increase).

    Time frame: From first dose of study drug up to Day 225

  4. Number of Participants With Potentially Clinically Relevant Clinical Laboratory Abnormalities

    Potentially clinically relevant laboratory abnormalities included: In units per liter \[U/L\] (alanine aminotransferase: male\[M\]/female\[F\] \>=3 x upper limit of normal (ULN); aspartate aminotransferase: M/F \>= 3 x ULN; creatine kinase: M/F \>= 3 x ULN); in milligrams per deciliter (mg/dL) (creatinine: M/F \>= 2.0; glucose: M/F \>= 200; urate: M \>=10.5, F \>=8.5); potassium \[milliequivalents per liter (mEq/L)\]: M/F \>=5.5, in percentage (%) (eosinophils/leukocytes: M/F\>=10%, hematocrit: M\<=37%/F\<=32% and 3 point decrease from baseline); hemoglobin (grams per deciliter \[g/dL\]): M\<=11.5/F\<=9.5; leukocytes \[10\^9 per liter (/L)\]: M/F\<=2.8 x 10\^3 per microliters (/uL); platelets (10\^9/L): M/F\>=700 x 10\^3/uL; glucose, urine and protein, urine: increase of \>=2 units; and prolactin (nanograms per milliliter \[ng/mL\]: M/F \> 1 x ULN.

    Time frame: From first dose of study drug up to Day 225

  5. Mean Change From Baseline in Simpson-Angus Neurologic Rating Scale (SAS) Total Score

    The SAS scale is used to evaluate extrapyramidal symptoms (EPS) and consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Each item is rated on a 5-point scale, with a score of range of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores for all 10 items, possible total score is 0 to 40. Negative change from baseline indicates less symptoms.

    Time frame: Baseline, Week 32

  6. Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Movement Score

    The AIMS assessment consists of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk movements (item 7), dyskinesias (items 8 through 10). Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms (for item 10, no awareness), and a score of 4 indicating a severe condition (for item 10, aware/severe distress). AIMS movement score is the sum of the ratings for the first seven items with the possible total scores of 0 to 28. Negative change from baseline indicates less symptoms.

    Time frame: Baseline, Week 32

  7. Mean Change From Baseline in Barnes Akathisia Rating Score (BARS) Global Score

    The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, participant distress due to akathisia, and global evaluation of akathisia. The first 3 items are rated on a 4-point scale, with a score of 0 representing absence of symptoms and a score of 3 representing a severe condition. The global clinical evaluation is made on a 6-point scale, with 0 representing absence of symptoms and a score of 5 representing severe akathisia. Total BARS score ranges from 0 to 14 where lower scores indicate less symptoms and negative change from baseline indicate less symptoms.

    Time frame: Baseline, Week 32

  8. Visual Analog Scale (VAS) Scores for Pain Perception of Aripiprazole 2M LAI 960 mg

    Injection-site pain was evaluated by mean VAS scores as reported by the participant after each injection at visits where an injection occurred. The last injection was the final injection for any given participant. Ratings ranged from 0 (no pain) to 100 (unbearably painful).

    Time frame: Day 1 (First injection) to Day 169 (Last injection)

  9. VAS Scores for Pain Perception of Aripiprazole IM Depot 400 mg

    Injection-site pain was evaluated by mean VAS scores as reported by the participant after each injection at visits where an injection occurred. The last injection was the final injection for any given participant. Ratings ranged from 0 (no pain) to 100 (unbearably painful).

    Time frame: Day 1 (First injection) to Day 197 (Last injection)

  10. Number of Participants With Injection Site Evaluations (Pain, Redness, Swelling, Induration) Measured by Investigator Rating After Aripiprazole 2M LAI 960 mg Injection

    Injection-site reactions were assessed by the investigator (or qualified designee) and the participant. Investigators rated localized pain, redness, swelling, and induration at the most recent injection site using a 4-point categorical scale (absent, mild, moderate, severe). The participant indicated the degree of pain at the most recent injection site using a VAS instrument. Ratings included were: 0 = absent, 1 = mild, 2 = moderate, 3 = severe. The last injection was the final injection for any given participant.

    Time frame: Day 1 (First injection) to Day 169 (Last injection)

  11. Number of Participants With Injection Site Evaluations (Pain, Redness, Swelling, Induration) Measured by Investigator Rating After Aripiprazole IM Depot 400 mg Injection

    Injection-site reactions were assessed by the investigator (or qualified designee) and the participant. Investigators rated localized pain, redness, swelling, and induration at the most recent injection site using a 4-point categorical scale (absent, mild, moderate, severe). The participant indicated the degree of pain at the most recent injection site using a VAS instrument. Ratings included were: 0 = absent, 1 = mild, 2 = moderate, 3 = severe. The last injection was the final injection for any given participant.

    Time frame: Day 1 (First injection) to Day 197 (Last injection)

  12. Number of Participants With Suicidality as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)

    C-SSRS was used to assess the suicidality of participants during the study. The assessment included "yes" or "no" responses for 5 questions, each related to suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan) and suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, suicide). Numeric ratings were provided for suicidal ideation: Score range of 1 (wish to be dead) to 5 (active suicidal ideation with specific plan and intent), higher total scores indicate more suicidal ideation; Suicidal behavior: Score range of 0 (no suicidal behavior) to 4 (actual suicide attempt), higher total scores indicate more suicidal behavior. Suicidality was defined as reporting any suicidal ideation or behavior.

    Time frame: Baseline to Day 225

  13. Plasma Concentration of Aripiprazole 56 Days Postdose (C56) of Aripiprazole 2M LAI 960 mg After the Fourth Dose

    Time frame: Day 225

  14. Plasma Concentration of Aripiprazole 28 Days Postdose (C28) of Aripiprazole IM Depot 400 mg After the Eighth Dose

    Time frame: Day 225

  15. Area Under the Plasma Concentration-Time Curve From Time 0 to 28 Days (AUC0-28) of Aripiprazole After the Seventh and Eighth Doses of Aripiprazole IM Depot 400 mg

    Time frame: Days 169 (predose and 4, 8, 12 hours post dose), 170, 171, 173, 176, 178, 181, 183, 186, 190, 197 (predose and 4, 8, 12 hours post dose), 198, 199, 201, 204, 206, 209, 211, 214, 218, 225

  16. Area Under the Plasma Concentration-Time Curve From Time 0 to 56 Days (AUC0-56) of Aripiprazole After the Fourth Dose of Aripiprazole 2M LAI 960 mg

    Time frame: Days 169 (predose and 4, 8, 12 hours post dose), 170, 171, 173, 176, 178, 181, 183, 186, 190, 197, 204, 211, 218, and 225

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Aripiprazole After First and Fourth Doses of Aripiprazole 2M LAI 960 mg

    Time frame: Days 1(predose [within 2 hours(h) prior to dosing]&4,8,12 h postdose),2,3,5,8,10,13,15,18,22,29,36,43,50,57(predose),85,113(predose),141,169(predose [within 2 h prior to dosing]& 4,8,12 h postdose),170,171,173,176,178,181,183,186,190,197,204,211,218 & 225

  2. Time to Reach the Maximum Plasma Concentration (Tmax) of Aripiprazole After First and Fourth Doses of Aripiprazole 2M LAI 960 mg

    Time frame: Days 1(predose [within 2 hours(h) prior to dosing]&4,8,12 h postdose),2,3,5,8,10,13,15,18,22,29,36,43,50,57(predose),85,113(predose),141,169(predose [within 2 h prior to dosing]& 4,8,12 h postdose),170,171,173,176,178,181,183,186,190,197,204,211,218 & 225

  3. AUC0-56 After the First Dose of Aripiprazole 2M LAI 960 mg

    Time frame: Days 1 (predose and 4, 8, 12 hours post-dose), 2, 3, 5, 8, 10, 13, 15, 18, 22, 29, 36, 43, 50 and 57 (pre-dose)

  4. Plasma Concentration of Aripiprazole 56 Days (C56) After the First Dose of Aripiprazole 2M LAI 960 mg

    Time frame: Predose on Day 57

  5. AUC0-28 After the Fourth Dose of Aripiprazole 2M LAI 960 mg

    Time frame: Days 169 (predose and 4, 8, 12 hours postdose), 170, 171, 173, 176, 178, 181, 183, 186, 190, and 197

  6. Area Under the Plasma Concentration-Time Curve From Time 29 to 56 Days (AUC29-56) After the Fourth Dose of Aripiprazole 2M LAI 960 mg

    Time frame: Days 204, 211, 218, and 225

  7. Peak-to-Trough Percent Fluctuation (PTF%) After the Fourth Dose of Aripiprazole 2M LAI 960 mg

    PTF% was determined as 100\*(Cmax - Cmin \[minimum plasma concentration of the drug\])/Caverage (average steady-state plasma drug concentration during multiple-dose administration) following fourth dose.

    Time frame: Days 169 (Predose [within 2 hours prior to dosing] and 4, 8, 12 hours post dose), 170, 171, 173, 176, 178, 181, 183, 186, 190, 197, 204, 211, 218, and 225

  8. Cmax of Aripiprazole After the First, Seventh, and Eighth Doses of Aripiprazole IM Depot 400 mg

    Time frame: Predose [within 2 hours prior to dosing; 4,8,12h postdose] on Days 1,169,197; Predose on Days 29,57,85,113,141; and on Days 2, 3, 5, 8, 10, 13, 15, 18, 22, 170, 171, 173, 176, 178, 181, 183, 186, 190,198, 199, 201, 204, 206, 209, 211, 214, 218, 225

  9. Tmax of Aripiprazole After the First, Seventh, and Eighth Doses of Aripiprazole IM Depot 400 mg

    Time frame: Predose [within 2 hours prior to dosing; 4,8,12h postdose] on Days 1,169,197; Predose on Days 29,57,85,113,141; and on Days 2, 3, 5, 8, 10, 13, 15, 18, 22, 170, 171, 173, 176, 178, 181, 183, 186, 190,198, 199, 201, 204, 206, 209, 211, 214, 218, 225

  10. AUC0-28 After the First Dose of Aripiprazole IM Depot 400 mg

    Time frame: Days 1 (predose and 4, 8, and 12 hours postdose), 2, 3, 5, 8, 10, 13, 15, 18, 22 and 29 (predose)

  11. Plasma Concentration of Aripiprazole 28 Days (C28) After the First Dose of Aripiprazole IM Depot 400 mg

    Time frame: Predose on Day 29

  12. PTF% After the Eighth Dose of Aripiprazole IM Depot 400 mg

    PTF% was determined as 100\*(Cmax - Cmin \[minimum plasma concentration of the drug\])/Caverage (average steady-state plasma drug concentration during multiple-dose administration) following eighth dose.

    Time frame: Days 197 (Predose [within 2 hours prior to dosing] and 4, 8, 12 hours post dose),198, 199, 201, 204, 206, 209, 211, 214, 218, 225

  13. Plasma Concentration of Aripiprazole 7 Days Post First Dose (C7) of Aripiprazole 2M LAI 960 mg

    Time frame: Day 8

  14. Plasma Concentration of Aripiprazole Post First Dose (C14) of Aripiprazole IM Depot 400 mg

    Time frame: Day 15

  15. Mean Change From Baseline in Positive and Negative Syndrome Scale Rating Criteria (PANSS) Total Score

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome). Higher scores indicate worse condition. The PANSS was assessed for schizophrenia participants only.

    Time frame: Baseline, Week 32

  16. Mean Change From Baseline in Clinical Global Impression - Severity Scale (CGI-S) Score

    The CGI-S is a standardized, clinician-administered global rating scale that measures disease severity. To assess CGI-S, the rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices include: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. The cumulative score range is 0-7. A higher score on the CGI-S represents a higher severity of disease. The CGI-S scale was assessed for schizophrenia participants only.

    Time frame: Baseline, Week 32

  17. Mean Change From Baseline in Clinical Global Impression - Improvement Scale (CGI-I) Score

    The CGI-I scale is a clinician rated scale which assesses the improvement of illness for each participant. To assess CGI-I, the rater or investigator rated the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared with the participant's condition at baseline. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. Scores range from 0 to 7. Higher scores indicate worse condition.

    Time frame: Baseline, Week 32

  18. Mean Change From Baseline in Subjective Well-Being Under Neuroleptic Treatment-Short Form (SWN-S) Total Score

    The participant's feeling of their own well-being was assessed using the 20-question SWN-S. The SWN-S was a validated self-report instrument that evaluated the participant's perception of well-being while receiving antipsychotic medication. The questionnaire consisted of 20 items (10 positive and 10 negative statements) and 5 subscales (mental functioning, social integration, emotional regulation, physical functioning, self-control) whose items followed in random order. For items marked with a '+', the response choices and scoring is not at all = 1, hardly at all = 2, a little = 3, somewhat = 4, much = 5, and very much = 6. For items marked with a '- ', the scoring is reversed; response choices and scoring are as follows: not at all = 6, hardly at all = 5, a little = 4, somewhat = 3, much = 2, very much = 1. SWN-S subscale score's each item was rated on a score of 1 (none) to 6 (severe), and total score ranged from 20 to 120, with higher scores indicating stronger subjective feeling

    Time frame: Baseline, Week 32

  19. Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

    The MADRS is a diagnostic questionnaire used by clinician to assess the participant's severity of depression. This scale consists of 10 items each with 7 defined grades of severity on 0 to 6 scale (reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts). MADRS total score is sum of 10 individual item scores ranging from 0-60 categorized as: 0 to 6: normal/symptoms absent, 7 to 19: mild depression, 20 to 34: moderate depression, and 35 to 60: severe depression. Higher score indicates more depressive symptoms. The MADRS was assessed for bipolar I disorder participants only.

    Time frame: Baseline, Week 32

  20. Mean Change From Baseline in Young Mania Rating Scale (YMRS) Total Score

    The YMRS is an 11-item, multiple-choice diagnostic questionnaire which psychiatrists use to assess the core symptoms of mania and is based on the participants subjective report of their condition. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. Total score is summed of 11 items. Total score range is from 0 to 60 and the higher score represent a worse outcome. The YMRS was assessed for bipolar I disorder participants only.

    Time frame: Baseline, Week 32

  21. Mean Change From Baseline in Clinical Global Impression - Bipolar Version (CGI-BP) Severity of Illness Score

    The CGI-BP scale refers to the global impression of the participants with respect to bipolar disorder. The scale rates the participant's severity of illness (CGI-BP-Severity: mania, depression, and overall bipolar illness) and change from preceding phase (CGI-BP change from preceding phase: mania, depression, and overall bipolar illness) based on a 7-point scale ranging from 1 (normal, not ill) to 7 (very severely ill). A negative change score signifies improvement. The CGI-BP was assessed for bipolar I disorder participants only.

    Time frame: Baseline, Week 32

07

Results

Posted Nov 18, 2023

Participant flow

Participants were enrolled in the study at 16 investigational sites in the United States from 01 August 2019 to 08 July 2020.

Participant flow — Overall Study
MilestoneAripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I DisorderAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder
Started132134
Safety sample132134
Efficacy sample132134
Completed10292
Not completed3042
Withdrew: Adverse event510
Withdrew: Lost to follow-up37
Withdrew: Protocol deviation22
Withdrew: Withdrawal by subject1618
Withdrew: Physician decision11
Withdrew: Due to covid-1923
Withdrew: Not due to covid-1911

Outcome measures

PrimaryNumber of Participants With One or More Treatment-Emergent Adverse Events (TEAEs)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. A TEAE is defined as an AE that started after investigational medicinal product (IMP) treatment; or if the event was continuous from baseline and was serious, IMP-related, or resulted in death, discontinuation, interruption, or reduction of the IMP.

Time frame:
From first dose of study drug up to 56 days (2M LAI 960 mg) or 28 days (IM depot 400 mg) post last dose of study drug (up to approximately 11 months)
Reported as:
Count of participants · Participants
Number of Participants With One or More Treatment-Emergent Adverse Events (TEAEs)
ParticipantsAripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I DisorderAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder
Number of Participants With One or More Treatment-Emergent Adverse Events (TEAEs)9495
PrimaryNumber of Participants With Potentially Clinically Relevant Vital Signs Abnormalities

Potentially clinically significant vital sign abnormalities included: heart rate supine (high: \>120 beats per minute \[BPM\] and increase \>=15 BPM; low: \<50 BPM and decrease \>=15 BPM), systolic blood pressure supine (high \>180 (millimetres of mercury \[mmHg\] and increase \>=20 mmHg); low: \<90 mmHg and decrease \>=20 mmHg), diastolic blood pressure supine (high: \>105 mmHg and increase \>=15 mmHg; low: \<50 mmHg and decrease \>=15 mmHg), heart rate standing (high: \>120 BPM and increase \>=15 BPM), systolic blood pressure standing (high: \>180 mmHg and increase \>= 20 mmHg; low: \<90 mmHg and decrease \>=20 mmHg), diastolic blood pressure standing (high: \>105 mmHg and increase \>=15 mmHg), weight in kilograms (kg) (high: increase \>=7%; low: decrease \>=7%), temperature (high: \>=37.8 degree celsius \[°C\] and increase \>=1.1°C), orthostatic hypotension (low: \>=20 mmHg decrease in systolic blood pressure and \>=25 BPM increase in heart rate from supine to standing.

Time frame:
From first dose of study drug up to Day 225
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Relevant Vital Signs Abnormalities
ParticipantsAripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I DisorderAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder
Heart Rate Supine: Low01
Heart Rate Supine: High21
Systolic Blood Pressure Supine: Low12
Systolic Blood Pressure Supine: High01
Diastolic Blood Pressure Supine: Low11
Diastolic Blood Pressure Supine: High11
Heart Rate Standing: High46
Systolic Blood Pressure Standing: Low14
Systolic Blood Pressure Standing: High02
Diastolic Blood Pressure Standing: High23
Weight: Low1211
Weight: High5254
Temperature: High44
Orthostatic Hypotension: Low22
PrimaryNumber of Participants With Potentially Clinically Relevant Electrocardiogram (ECG) Abnormalities

Potentially clinically significant ECG abnormalities included rate: bradycardia (vent \<=50 BPM\] and decrease \>=15 BPM); rhythm: sinus bradycardia (\<= 50 BPM and decrease \>= 15 BPM and no current diagnosis of atrial fibrillation, atrial flutter, or other rhythm abnormality); supraventricular premature beat (not present at baseline and present post baseline); ventricular premature beat (not present at baseline and present post baseline); conduction: right bundle branch block (not present at baseline and present post baseline); ST/T morphology: myocardial ischemia and symmetrical T-wave inversion (not present at baseline and present post baseline), QTcB, QTcF, and QTcN (\>=450 milliseconds \[msec\] and \>= 10% increase).

Time frame:
From first dose of study drug up to Day 225
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Relevant Electrocardiogram (ECG) Abnormalities
ParticipantsAripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I DisorderAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder
Bradycardia02
Sinus Bradycardia02
Supraventricular Premature Beat1310
Ventricular Premature Beat1712
Right Bundle Branch Block10
Myocardial Ischemia37
Symmetrical T-Wave Inversion1212
QTcB11
QTcF01
QTcN01
PrimaryNumber of Participants With Potentially Clinically Relevant Clinical Laboratory Abnormalities

Potentially clinically relevant laboratory abnormalities included: In units per liter \[U/L\] (alanine aminotransferase: male\[M\]/female\[F\] \>=3 x upper limit of normal (ULN); aspartate aminotransferase: M/F \>= 3 x ULN; creatine kinase: M/F \>= 3 x ULN); in milligrams per deciliter (mg/dL) (creatinine: M/F \>= 2.0; glucose: M/F \>= 200; urate: M \>=10.5, F \>=8.5); potassium \[milliequivalents per liter (mEq/L)\]: M/F \>=5.5, in percentage (%) (eosinophils/leukocytes: M/F\>=10%, hematocrit: M\<=37%/F\<=32% and 3 point decrease from baseline); hemoglobin (grams per deciliter \[g/dL\]): M\<=11.5/F\<=9.5; leukocytes \[10\^9 per liter (/L)\]: M/F\<=2.8 x 10\^3 per microliters (/uL); platelets (10\^9/L): M/F\>=700 x 10\^3/uL; glucose, urine and protein, urine: increase of \>=2 units; and prolactin (nanograms per milliliter \[ng/mL\]: M/F \> 1 x ULN.

Time frame:
From first dose of study drug up to Day 225
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Relevant Clinical Laboratory Abnormalities
ParticipantsAripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I DisorderAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder
High Alanine Aminotransferase (U/L)12
High Aspartate Aminotransferase (U/L)02
High Creatine Kinase (U/L)121
High Creatinine (mg/dL)21
High Glucose (mg/dL)73
High Potassium (mEq/L)54
High Urate (mg/dL)20
High Eosinophils/Leukocytes (%)20
Low Hematocrit (%)78
Low Hemoglobin (g/dL)49
Low Leukocytes (10^9/L)03
High Platelets (10^9/L)01
High Glucose, Urine56
High Protein, Urine12
High Prolactin (ng/mL)24
PrimaryMean Change From Baseline in Simpson-Angus Neurologic Rating Scale (SAS) Total Score

The SAS scale is used to evaluate extrapyramidal symptoms (EPS) and consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Each item is rated on a 5-point scale, with a score of range of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores for all 10 items, possible total score is 0 to 40. Negative change from baseline indicates less symptoms.

Time frame:
Baseline, Week 32
Reported as:
Mean · score on a scale
Mean Change From Baseline in Simpson-Angus Neurologic Rating Scale (SAS) Total Score
score on a scaleAripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I DisorderAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder
Baseline0.2 ± 0.60.2 ± 0.4
Change From Baseline at Week 32-0.0 ± 0.70.1 ± 0.6
PrimaryMean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Movement Score

The AIMS assessment consists of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk movements (item 7), dyskinesias (items 8 through 10). Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms (for item 10, no awareness), and a score of 4 indicating a severe condition (for item 10, aware/severe distress). AIMS movement score is the sum of the ratings for the first seven items with the possible total scores of 0 to 28. Negative change from baseline indicates less symptoms.

Time frame:
Baseline, Week 32
Reported as:
Mean · score on a scale
Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Movement Score
score on a scaleAripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I DisorderAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder
Baseline0.1 ± 1.00.1 ± 0.7
Change from Baseline at Week 320.0 ± 0.5-0.1 ± 0.6
PrimaryMean Change From Baseline in Barnes Akathisia Rating Score (BARS) Global Score

The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, participant distress due to akathisia, and global evaluation of akathisia. The first 3 items are rated on a 4-point scale, with a score of 0 representing absence of symptoms and a score of 3 representing a severe condition. The global clinical evaluation is made on a 6-point scale, with 0 representing absence of symptoms and a score of 5 representing severe akathisia. Total BARS score ranges from 0 to 14 where lower scores indicate less symptoms and negative change from baseline indicate less symptoms.

Time frame:
Baseline, Week 32
Reported as:
Mean · score on a scale
Mean Change From Baseline in Barnes Akathisia Rating Score (BARS) Global Score
score on a scaleAripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I DisorderAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder
Baseline0.1 ± 0.30.1 ± 0.3
Change from Baseline at Week 320.1 ± 0.60.1 ± 0.4
PrimaryVisual Analog Scale (VAS) Scores for Pain Perception of Aripiprazole 2M LAI 960 mg

Injection-site pain was evaluated by mean VAS scores as reported by the participant after each injection at visits where an injection occurred. The last injection was the final injection for any given participant. Ratings ranged from 0 (no pain) to 100 (unbearably painful).

Time frame:
Day 1 (First injection) to Day 169 (Last injection)
Reported as:
Mean · score on a scale
Visual Analog Scale (VAS) Scores for Pain Perception of Aripiprazole 2M LAI 960 mg
score on a scaleAripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder
First Injection: Predose1.0 ± 1.29
First Injection: Post dose3.7 ± 9.09
Second Injection: Predose1.0 ± 2.32
Second Injection: Post dose1.4 ± 2.78
Third Injection: Predose1.0 ± 2.58
Third Injection: Post dose2.0 ± 6.01
Fourth Injection: Predose0.8 ± 1.02
Fourth Injection: Post dose1.4 ± 4.38
Last Injection: Predose0.8 ± 1.03
Last Injection: Post dose1.4 ± 3.98
PrimaryVAS Scores for Pain Perception of Aripiprazole IM Depot 400 mg

Injection-site pain was evaluated by mean VAS scores as reported by the participant after each injection at visits where an injection occurred. The last injection was the final injection for any given participant. Ratings ranged from 0 (no pain) to 100 (unbearably painful).

Time frame:
Day 1 (First injection) to Day 197 (Last injection)
Reported as:
Mean · score on a scale
VAS Scores for Pain Perception of Aripiprazole IM Depot 400 mg
score on a scaleAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder
First Injection: Predose1.6 ± 2.37
First Injection: Post dose3.0 ± 5.28
Second Injection: Predose1.5 ± 2.66
Second Injection: Post dose1.6 ± 3.09
Third Injection: Predose0.8 ± 1.10
Third Injection: Post dose1.2 ± 2.09
Fourth Injection: Predose0.7 ± 0.79
Fourth Injection: Post dose1.1 ± 2.39
Fifth Injection: Predose0.7 ± 0.82
Fifth Injection: Post dose0.8 ± 1.12
Sixth Injection: Predose0.8 ± 1.11
Sixth Injection: Post dose0.8 ± 1.20
Seventh Injection: Predose0.6 ± 0.77
Seventh Injection: Post dose1.0 ± 2.30
Eighth Injection: Predose0.6 ± 0.69
Eighth Injection: Post dose0.8 ± 0.85
Last Injection: Predose0.9 ± 1.00
Last Injection: Post dose1.3 ± 2.62
PrimaryNumber of Participants With Injection Site Evaluations (Pain, Redness, Swelling, Induration) Measured by Investigator Rating After Aripiprazole 2M LAI 960 mg Injection

Injection-site reactions were assessed by the investigator (or qualified designee) and the participant. Investigators rated localized pain, redness, swelling, and induration at the most recent injection site using a 4-point categorical scale (absent, mild, moderate, severe). The participant indicated the degree of pain at the most recent injection site using a VAS instrument. Ratings included were: 0 = absent, 1 = mild, 2 = moderate, 3 = severe. The last injection was the final injection for any given participant.

Time frame:
Day 1 (First injection) to Day 169 (Last injection)
Reported as:
Count of participants · Participants
Number of Participants With Injection Site Evaluations (Pain, Redness, Swelling, Induration) Measured by Investigator Rating After Aripiprazole 2M LAI 960 mg Injection
ParticipantsAripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder
First Injection: Mild Pain11
Second Injection: Mild Pain2
Third Injection: Mild Pain5
Fourth Injection: Mild Pain5
Last injection: Mild Pain5
First injection: Mild Redness3
Third injection: Mild Redness1
Last injection: Mild Redness1
PrimaryNumber of Participants With Injection Site Evaluations (Pain, Redness, Swelling, Induration) Measured by Investigator Rating After Aripiprazole IM Depot 400 mg Injection

Injection-site reactions were assessed by the investigator (or qualified designee) and the participant. Investigators rated localized pain, redness, swelling, and induration at the most recent injection site using a 4-point categorical scale (absent, mild, moderate, severe). The participant indicated the degree of pain at the most recent injection site using a VAS instrument. Ratings included were: 0 = absent, 1 = mild, 2 = moderate, 3 = severe. The last injection was the final injection for any given participant.

Time frame:
Day 1 (First injection) to Day 197 (Last injection)
Reported as:
Count of participants · Participants
Number of Participants With Injection Site Evaluations (Pain, Redness, Swelling, Induration) Measured by Investigator Rating After Aripiprazole IM Depot 400 mg Injection
ParticipantsAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder
First Injection: Mild Pain7
Second Injection: Mild Pain3
Third Injection: Mild Pain7
Fourth Injection: Mild Pain1
Fifth Injection: Mild Pain3
Seventh Injection: Mild Pain1
Eighth Injection: Mild Pain1
Last injection: Mild Pain3
First injection: Mild Redness1
Second injection: Mild Redness3
PrimaryNumber of Participants With Suicidality as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)

C-SSRS was used to assess the suicidality of participants during the study. The assessment included "yes" or "no" responses for 5 questions, each related to suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan) and suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, suicide). Numeric ratings were provided for suicidal ideation: Score range of 1 (wish to be dead) to 5 (active suicidal ideation with specific plan and intent), higher total scores indicate more suicidal ideation; Suicidal behavior: Score range of 0 (no suicidal behavior) to 4 (actual suicide attempt), higher total scores indicate more suicidal behavior. Suicidality was defined as reporting any suicidal ideation or behavior.

Time frame:
Baseline to Day 225
Reported as:
Count of participants · Participants
Number of Participants With Suicidality as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
ParticipantsAripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I DisorderAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder
Number of Participants With Suicidality as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)44
PrimaryPlasma Concentration of Aripiprazole 56 Days Postdose (C56) of Aripiprazole 2M LAI 960 mg After the Fourth Dose
Time frame:
Day 225
Reported as:
Mean · ng/mL (nanogram per milliliter)
Plasma Concentration of Aripiprazole 56 Days Postdose (C56) of Aripiprazole 2M LAI 960 mg After the Fourth Dose
ng/mL (nanogram per milliliter)Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder
Plasma Concentration of Aripiprazole 56 Days Postdose (C56) of Aripiprazole 2M LAI 960 mg After the Fourth Dose250 ± 128
PrimaryPlasma Concentration of Aripiprazole 28 Days Postdose (C28) of Aripiprazole IM Depot 400 mg After the Eighth Dose
Time frame:
Day 225
Reported as:
Mean · ng/mL
Plasma Concentration of Aripiprazole 28 Days Postdose (C28) of Aripiprazole IM Depot 400 mg After the Eighth Dose
ng/mLAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder
Plasma Concentration of Aripiprazole 28 Days Postdose (C28) of Aripiprazole IM Depot 400 mg After the Eighth Dose257 ± 162
PrimaryArea Under the Plasma Concentration-Time Curve From Time 0 to 28 Days (AUC0-28) of Aripiprazole After the Seventh and Eighth Doses of Aripiprazole IM Depot 400 mg
Time frame:
Days 169 (predose and 4, 8, 12 hours post dose), 170, 171, 173, 176, 178, 181, 183, 186, 190, 197 (predose and 4, 8, 12 hours post dose), 198, 199, 201, 204, 206, 209, 211, 214, 218, 225
Reported as:
Mean · day*ng/mL
Area Under the Plasma Concentration-Time Curve From Time 0 to 28 Days (AUC0-28) of Aripiprazole After the Seventh and Eighth Doses of Aripiprazole IM Depot 400 mg
day*ng/mLAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder
AUC0-28 After Seventh Dose (Day 169)7760 ± 4300
AUC0-28 After Eighth Dose (Day 197)7840 ± 5170
PrimaryArea Under the Plasma Concentration-Time Curve From Time 0 to 56 Days (AUC0-56) of Aripiprazole After the Fourth Dose of Aripiprazole 2M LAI 960 mg
Time frame:
Days 169 (predose and 4, 8, 12 hours post dose), 170, 171, 173, 176, 178, 181, 183, 186, 190, 197, 204, 211, 218, and 225
Reported as:
Mean · day*ng/mL
Area Under the Plasma Concentration-Time Curve From Time 0 to 56 Days (AUC0-56) of Aripiprazole After the Fourth Dose of Aripiprazole 2M LAI 960 mg
day*ng/mLAripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder
Area Under the Plasma Concentration-Time Curve From Time 0 to 56 Days (AUC0-56) of Aripiprazole After the Fourth Dose of Aripiprazole 2M LAI 960 mg14700 ± 7460
SecondaryMaximum Observed Plasma Concentration (Cmax) of Aripiprazole After First and Fourth Doses of Aripiprazole 2M LAI 960 mg
Time frame:
Days 1(predose [within 2 hours(h) prior to dosing]&4,8,12 h postdose),2,3,5,8,10,13,15,18,22,29,36,43,50,57(predose),85,113(predose),141,169(predose [within 2 h prior to dosing]& 4,8,12 h postdose),170,171,173,176,178,181,183,186,190,197,204,211,218 & 225
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Aripiprazole After First and Fourth Doses of Aripiprazole 2M LAI 960 mg
ng/mLAripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder
Cmax After First Dose (Day 1)286 ± 203
Cmax After Fourth Dose (Day 169)342 ± 157
SecondaryTime to Reach the Maximum Plasma Concentration (Tmax) of Aripiprazole After First and Fourth Doses of Aripiprazole 2M LAI 960 mg
Time frame:
Days 1(predose [within 2 hours(h) prior to dosing]&4,8,12 h postdose),2,3,5,8,10,13,15,18,22,29,36,43,50,57(predose),85,113(predose),141,169(predose [within 2 h prior to dosing]& 4,8,12 h postdose),170,171,173,176,178,181,183,186,190,197,204,211,218 & 225
Reported as:
Median · days
Time to Reach the Maximum Plasma Concentration (Tmax) of Aripiprazole After First and Fourth Doses of Aripiprazole 2M LAI 960 mg
daysAripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder
Tmax After First Dose (Day 1)8.58 (3.92 to 55.9)
Tmax After Fourth Dose (Day 169)28.0 (0.930 to 49.0)
SecondaryAUC0-56 After the First Dose of Aripiprazole 2M LAI 960 mg
Time frame:
Days 1 (predose and 4, 8, 12 hours post-dose), 2, 3, 5, 8, 10, 13, 15, 18, 22, 29, 36, 43, 50 and 57 (pre-dose)
Reported as:
Mean · day*ng/mL
AUC0-56 After the First Dose of Aripiprazole 2M LAI 960 mg
day*ng/mLAripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder
AUC0-56 After the First Dose of Aripiprazole 2M LAI 960 mg9180 ± 4940
SecondaryPlasma Concentration of Aripiprazole 56 Days (C56) After the First Dose of Aripiprazole 2M LAI 960 mg
Time frame:
Predose on Day 57
Reported as:
Mean · ng/mL
Plasma Concentration of Aripiprazole 56 Days (C56) After the First Dose of Aripiprazole 2M LAI 960 mg
ng/mLAripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder
Plasma Concentration of Aripiprazole 56 Days (C56) After the First Dose of Aripiprazole 2M LAI 960 mg165 ± 91.7
SecondaryAUC0-28 After the Fourth Dose of Aripiprazole 2M LAI 960 mg
Time frame:
Days 169 (predose and 4, 8, 12 hours postdose), 170, 171, 173, 176, 178, 181, 183, 186, 190, and 197
Reported as:
Mean · day*ng/mL
AUC0-28 After the Fourth Dose of Aripiprazole 2M LAI 960 mg
day*ng/mLAripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder
AUC0-28 After the Fourth Dose of Aripiprazole 2M LAI 960 mg7190 ± 3470
SecondaryArea Under the Plasma Concentration-Time Curve From Time 29 to 56 Days (AUC29-56) After the Fourth Dose of Aripiprazole 2M LAI 960 mg
Time frame:
Days 204, 211, 218, and 225
Reported as:
Mean · day*ng/mL
Area Under the Plasma Concentration-Time Curve From Time 29 to 56 Days (AUC29-56) After the Fourth Dose of Aripiprazole 2M LAI 960 mg
day*ng/mLAripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder
Area Under the Plasma Concentration-Time Curve From Time 29 to 56 Days (AUC29-56) After the Fourth Dose of Aripiprazole 2M LAI 960 mg7500 ± 4200
SecondaryPeak-to-Trough Percent Fluctuation (PTF%) After the Fourth Dose of Aripiprazole 2M LAI 960 mg

PTF% was determined as 100\*(Cmax - Cmin \[minimum plasma concentration of the drug\])/Caverage (average steady-state plasma drug concentration during multiple-dose administration) following fourth dose.

Time frame:
Days 169 (Predose [within 2 hours prior to dosing] and 4, 8, 12 hours post dose), 170, 171, 173, 176, 178, 181, 183, 186, 190, 197, 204, 211, 218, and 225
Reported as:
Mean · percentage fluctuation
Peak-to-Trough Percent Fluctuation (PTF%) After the Fourth Dose of Aripiprazole 2M LAI 960 mg
percentage fluctuationAripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder
Peak-to-Trough Percent Fluctuation (PTF%) After the Fourth Dose of Aripiprazole 2M LAI 960 mg63.4 ± 25.1
SecondaryCmax of Aripiprazole After the First, Seventh, and Eighth Doses of Aripiprazole IM Depot 400 mg
Time frame:
Predose [within 2 hours prior to dosing; 4,8,12h postdose] on Days 1,169,197; Predose on Days 29,57,85,113,141; and on Days 2, 3, 5, 8, 10, 13, 15, 18, 22, 170, 171, 173, 176, 178, 181, 183, 186, 190,198, 199, 201, 204, 206, 209, 211, 214, 218, 225
Reported as:
Mean · ng/mL
Cmax of Aripiprazole After the First, Seventh, and Eighth Doses of Aripiprazole IM Depot 400 mg
ng/mLAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder
Cmax After First Dose (Day 1)280 ± 123
Cmax After Seventh Dose (Day 169)339 ± 168
Cmax After Eighth Dose (Day 197)344 ± 212
SecondaryTmax of Aripiprazole After the First, Seventh, and Eighth Doses of Aripiprazole IM Depot 400 mg
Time frame:
Predose [within 2 hours prior to dosing; 4,8,12h postdose] on Days 1,169,197; Predose on Days 29,57,85,113,141; and on Days 2, 3, 5, 8, 10, 13, 15, 18, 22, 170, 171, 173, 176, 178, 181, 183, 186, 190,198, 199, 201, 204, 206, 209, 211, 214, 218, 225
Reported as:
Median · days
Tmax of Aripiprazole After the First, Seventh, and Eighth Doses of Aripiprazole IM Depot 400 mg
daysAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder
Tmax After First Dose (Day 1)9.04 (3.83 to 27.9)
Tmax After Seventh Dose (Day 169)6.97 (1.05 to 28.0)
Tmax After Eighth Dose (Day 197)4.07 (0 to 28.0)
SecondaryAUC0-28 After the First Dose of Aripiprazole IM Depot 400 mg
Time frame:
Days 1 (predose and 4, 8, and 12 hours postdose), 2, 3, 5, 8, 10, 13, 15, 18, 22 and 29 (predose)
Reported as:
Mean · day*ng/mL
AUC0-28 After the First Dose of Aripiprazole IM Depot 400 mg
day*ng/mLAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder
AUC0-28 After the First Dose of Aripiprazole IM Depot 400 mg5030 ± 2580
SecondaryPlasma Concentration of Aripiprazole 28 Days (C28) After the First Dose of Aripiprazole IM Depot 400 mg
Time frame:
Predose on Day 29
Reported as:
Mean · ng/mL
Plasma Concentration of Aripiprazole 28 Days (C28) After the First Dose of Aripiprazole IM Depot 400 mg
ng/mLAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder
Plasma Concentration of Aripiprazole 28 Days (C28) After the First Dose of Aripiprazole IM Depot 400 mg112 ± 82.9
SecondaryPTF% After the Eighth Dose of Aripiprazole IM Depot 400 mg

PTF% was determined as 100\*(Cmax - Cmin \[minimum plasma concentration of the drug\])/Caverage (average steady-state plasma drug concentration during multiple-dose administration) following eighth dose.

Time frame:
Days 197 (Predose [within 2 hours prior to dosing] and 4, 8, 12 hours post dose),198, 199, 201, 204, 206, 209, 211, 214, 218, 225
Reported as:
Mean · percentage fluctuation
PTF% After the Eighth Dose of Aripiprazole IM Depot 400 mg
percentage fluctuationAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder
PTF% After the Eighth Dose of Aripiprazole IM Depot 400 mg48.3 ± 19.0
SecondaryPlasma Concentration of Aripiprazole 7 Days Post First Dose (C7) of Aripiprazole 2M LAI 960 mg
Time frame:
Day 8
Reported as:
Mean · ng/mL
Plasma Concentration of Aripiprazole 7 Days Post First Dose (C7) of Aripiprazole 2M LAI 960 mg
ng/mLAripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder
Plasma Concentration of Aripiprazole 7 Days Post First Dose (C7) of Aripiprazole 2M LAI 960 mg221 ± 178
SecondaryPlasma Concentration of Aripiprazole Post First Dose (C14) of Aripiprazole IM Depot 400 mg
Time frame:
Day 15
Reported as:
Mean · ng/mL
Plasma Concentration of Aripiprazole Post First Dose (C14) of Aripiprazole IM Depot 400 mg
ng/mLAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder
Plasma Concentration of Aripiprazole Post First Dose (C14) of Aripiprazole IM Depot 400 mg229 ± 121
SecondaryMean Change From Baseline in Positive and Negative Syndrome Scale Rating Criteria (PANSS) Total Score

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome). Higher scores indicate worse condition. The PANSS was assessed for schizophrenia participants only.

Time frame:
Baseline, Week 32
Reported as:
Mean · score on a scale
Mean Change From Baseline in Positive and Negative Syndrome Scale Rating Criteria (PANSS) Total Score
score on a scaleAripiprazole 2M LAI 960 mg: SchizophreniaAripiprazole IM Depot 400 mg: Schizophrenia
Mean Change From Baseline in Positive and Negative Syndrome Scale Rating Criteria (PANSS) Total Score-2.6 ± 11.7-1.7 ± 8.5
SecondaryMean Change From Baseline in Clinical Global Impression - Severity Scale (CGI-S) Score

The CGI-S is a standardized, clinician-administered global rating scale that measures disease severity. To assess CGI-S, the rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices include: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. The cumulative score range is 0-7. A higher score on the CGI-S represents a higher severity of disease. The CGI-S scale was assessed for schizophrenia participants only.

Time frame:
Baseline, Week 32
Reported as:
Mean · score on a scale
Mean Change From Baseline in Clinical Global Impression - Severity Scale (CGI-S) Score
score on a scaleAripiprazole 2M LAI 960 mg: SchizophreniaAripiprazole IM Depot 400 mg: Schizophrenia
Mean Change From Baseline in Clinical Global Impression - Severity Scale (CGI-S) Score-0.3 ± 0.6-0.1 ± 0.7
SecondaryMean Change From Baseline in Clinical Global Impression - Improvement Scale (CGI-I) Score

The CGI-I scale is a clinician rated scale which assesses the improvement of illness for each participant. To assess CGI-I, the rater or investigator rated the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared with the participant's condition at baseline. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. Scores range from 0 to 7. Higher scores indicate worse condition.

Time frame:
Baseline, Week 32
Reported as:
Mean · score on a scale
Mean Change From Baseline in Clinical Global Impression - Improvement Scale (CGI-I) Score
score on a scaleAripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I DisorderAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder
Mean Change From Baseline in Clinical Global Impression - Improvement Scale (CGI-I) Score3.4 ± 1.13.5 ± 1.1
SecondaryMean Change From Baseline in Subjective Well-Being Under Neuroleptic Treatment-Short Form (SWN-S) Total Score

The participant's feeling of their own well-being was assessed using the 20-question SWN-S. The SWN-S was a validated self-report instrument that evaluated the participant's perception of well-being while receiving antipsychotic medication. The questionnaire consisted of 20 items (10 positive and 10 negative statements) and 5 subscales (mental functioning, social integration, emotional regulation, physical functioning, self-control) whose items followed in random order. For items marked with a '+', the response choices and scoring is not at all = 1, hardly at all = 2, a little = 3, somewhat = 4, much = 5, and very much = 6. For items marked with a '- ', the scoring is reversed; response choices and scoring are as follows: not at all = 6, hardly at all = 5, a little = 4, somewhat = 3, much = 2, very much = 1. SWN-S subscale score's each item was rated on a score of 1 (none) to 6 (severe), and total score ranged from 20 to 120, with higher scores indicating stronger subjective feeling

Time frame:
Baseline, Week 32
Reported as:
Mean · score on a scale
Mean Change From Baseline in Subjective Well-Being Under Neuroleptic Treatment-Short Form (SWN-S) Total Score
score on a scaleAripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I DisorderAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder
Mean Change From Baseline in Subjective Well-Being Under Neuroleptic Treatment-Short Form (SWN-S) Total Score3.2 ± 15.80.5 ± 18.2
SecondaryMean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

The MADRS is a diagnostic questionnaire used by clinician to assess the participant's severity of depression. This scale consists of 10 items each with 7 defined grades of severity on 0 to 6 scale (reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts). MADRS total score is sum of 10 individual item scores ranging from 0-60 categorized as: 0 to 6: normal/symptoms absent, 7 to 19: mild depression, 20 to 34: moderate depression, and 35 to 60: severe depression. Higher score indicates more depressive symptoms. The MADRS was assessed for bipolar I disorder participants only.

Time frame:
Baseline, Week 32
Reported as:
Mean · score on a scale
Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
score on a scaleAripiprazole 2M LAI 960 mg: Bipolar I DisorderAripiprazole IM Depot 400 mg: Bipolar I Disorder
Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score-3.5 ± 9.1-3.3 ± 12.5
SecondaryMean Change From Baseline in Young Mania Rating Scale (YMRS) Total Score

The YMRS is an 11-item, multiple-choice diagnostic questionnaire which psychiatrists use to assess the core symptoms of mania and is based on the participants subjective report of their condition. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. Total score is summed of 11 items. Total score range is from 0 to 60 and the higher score represent a worse outcome. The YMRS was assessed for bipolar I disorder participants only.

Time frame:
Baseline, Week 32
Reported as:
Mean · score on a scale
Mean Change From Baseline in Young Mania Rating Scale (YMRS) Total Score
score on a scaleAripiprazole 2M LAI 960 mg: Bipolar I DisorderAripiprazole IM Depot 400 mg: Bipolar I Disorder
Mean Change From Baseline in Young Mania Rating Scale (YMRS) Total Score-1.9 ± 7.1-4.7 ± 7.7
SecondaryMean Change From Baseline in Clinical Global Impression - Bipolar Version (CGI-BP) Severity of Illness Score

The CGI-BP scale refers to the global impression of the participants with respect to bipolar disorder. The scale rates the participant's severity of illness (CGI-BP-Severity: mania, depression, and overall bipolar illness) and change from preceding phase (CGI-BP change from preceding phase: mania, depression, and overall bipolar illness) based on a 7-point scale ranging from 1 (normal, not ill) to 7 (very severely ill). A negative change score signifies improvement. The CGI-BP was assessed for bipolar I disorder participants only.

Time frame:
Baseline, Week 32
Reported as:
Mean · score on a scale
Mean Change From Baseline in Clinical Global Impression - Bipolar Version (CGI-BP) Severity of Illness Score
score on a scaleAripiprazole 2M LAI 960 mg: Bipolar I DisorderAripiprazole IM Depot 400 mg: Bipolar I Disorder
Mean Change From Baseline in Clinical Global Impression - Bipolar Version (CGI-BP) Severity of Illness Score-0.2 ± 1.0-0.6 ± 1.2

Adverse events

Collected over From first dose of study drug up to 56 days (2M LAI 960 mg) or 28 days (IM depot 400 mg) post last dose of study drug (up to approximately 11 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder1/132 (0.8%)6/132 (4.5%)92/132 (69.7%)
Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder0/134 (0%)8/134 (6%)92/134 (68.7%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventAripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I DisorderAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder
Hallucination, auditoryPsychiatric disorders2/1320/134
Cardiac ArrestCardiac disorders1/1320/134
CellulitisInfections and infestations1/1320/134
AkathisiaNervous system disorders1/1321/134
Psychotic DisorderPsychiatric disorders1/1321/134
Cholecystitis AcuteHepatobiliary disorders0/1321/134
Septic ShockInfections and infestations0/1321/134
Adenocarcinoma of ColonNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1321/134
DepressionPsychiatric disorders0/1321/134
Depressive SymptomPsychiatric disorders0/1321/134
Most frequent other events
Showing 10 of 141
Most frequent other events
EventAripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I DisorderAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder
Weight IncreasedInvestigations30/13228/134
Injection Site PainGeneral disorders24/13212/134
AkathisiaNervous system disorders13/13212/134
AnxietyPsychiatric disorders11/13210/134
InsomniaPsychiatric disorders10/13211/134
HeadacheNervous system disorders10/1325/134
ToothacheGastrointestinal disorders2/13210/134
ConstipationGastrointestinal disorders8/1328/134
DiarrhoeaGastrointestinal disorders6/1321/134
Upper Respiratory Tract InfectionInfections and infestations6/1322/134

Baseline characteristics

Randomized sample consisted of all participants who were randomized.

Age, Continuous
Age, Continuous(years)Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I DisorderAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I DisorderTotal
Mean47.8 ± 10.846.8 ± 11.747.3 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I DisorderAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I DisorderTotal
Female424890
Male9086176
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I DisorderAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I DisorderTotal
Hispanic or Latino121123
Not Hispanic or Latino119122241
Unknown or Not Reported112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I DisorderAripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I DisorderTotal
Race — White293362
Race — Black or African American9995194
Race — Asian347
Race — Other123
08

Study locations

19 sites
  • Woodland International Research Group
    Little Rock, Arkansas 72211, United States
  • Woodland International Research Group
    Rogers, Arkansas 72758, United States
  • CITrials - Bellflower
    Bellflower, California 90706, United States
  • Collaborative Neuroscience Network
    Garden Grove, California 92845, United States
  • California Clinical Trials Medical Group
    Glendale, California 91206, United States
  • Synergy Research Centers
    Lemon Grove, California 91945, United States
  • NRC Research Institute
    Orange, California 92868, United States
  • California Neuropsychopharmacology Clinical Research Institute San Diego
    San Diego, California 92102, United States
  • Collaborative Neuroscience Network - South Bay
    Torrance, California 90502, United States
  • Research Centers of America
    Hollywood, Florida 33024, United States
  • Segal Institute For Clinical Research - West Broward Outpatient Clinic
    Miami Lakes, Florida 33016, United States
  • Atlanta Center for Medical Research - Atlanta
    Atlanta, Georgia 30331, United States
  • CBH Health
    Gaithersburg, Maryland 20877, United States
  • St. Louis Clinical Trials
    Saint Louis, Missouri 63141, United States
  • Altea Research Institute - Las Vegas
    Las Vegas, Nevada 89102, United States
  • Hassman Research Institute
    Marlton, New Jersey 08009, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • Carolina Clinical Trials
    Charleston, South Carolina 29407, United States
  • Community Clinical Research
    Austin, Texas 78754, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Jul 2020, 11 months.

Results were first posted in Nov 2023, 3 years 4 months after primary completion. A results delay was requested in Jun 2021.

Of 18 phase 1/2 interventional studies under Schizophrenia, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 70. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2019
First posted
Jul 23, 2019
StartActual
Aug 1, 2019
Primary completionActual
Jul 8, 2020
CompletionActual
Jul 8, 2020
Results delay requested
Jun 16, 2021
Results first posted
Nov 18, 2023
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04030143
Responsible party
Sponsor
First posted
Jul 23, 2019
Start date
Aug 1, 2019
Primary completion
Jul 8, 2020
Completion
Jul 8, 2020
Results posted
Nov 18, 2023
Last update
Nov 18, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion